{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:02:49Z","timestamp":1760144569656,"version":"build-2065373602"},"reference-count":106,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.cjca.2012.03.017","type":"journal-article","created":{"date-parts":[[2012,8,15]],"date-time":"2012-08-15T01:46:13Z","timestamp":1344995173000},"page":"667-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management"],"prefix":"10.1016","volume":"28","author":[{"given":"Pamela M.","family":"Katz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2012.03.017_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib4","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib9","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib10","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib11","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib12","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib13","doi-asserted-by":"crossref","first-page":"F34","DOI":"10.1093\/eurheartj\/sui041","article-title":"Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy","volume":"7","author":"Brown","year":"2005","journal-title":"European Heart Journal Supplement"},{"key":"10.1016\/j.cjca.2012.03.017_bib14","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/0002-9149(91)90924-A","article-title":"Prevalence of risk factors in men with premature coronary artery disease","volume":"67","author":"Genest","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2012.03.017_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib17","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","article-title":"High-density lipoprotein cholesterol as a predictor of coronary heart disease risk","volume":"124","author":"Assmann","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2012.03.017_bib18","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJM199006143222403","article-title":"Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease","volume":"322","author":"Pekkanen","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib20","doi-asserted-by":"crossref","unstructured":"Leiter LA, Fitchett DH, Gilbert RE, et al. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol;27:e1-33.","DOI":"10.1016\/j.cjca.2010.12.054"},{"key":"10.1016\/j.cjca.2012.03.017_bib21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib22","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1161\/01.ATV.0000092947.15939.93","article-title":"Genetics of increased HDL cholesterol levels: insights into the relationship between HDL metabolism and atherosclerosis","volume":"23","author":"Cuchel","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.03.017_bib23","doi-asserted-by":"crossref","first-page":"III8","DOI":"10.1161\/01.CIR.0000131512.50667.46","article-title":"HDL cholesterol and protective factors in atherosclerosis","volume":"109","author":"Assmann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib24","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1210\/jc.2010-0163","article-title":"The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease","volume":"96","author":"Brewer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cjca.2012.03.017_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/CS20080106","article-title":"High-density lipoproteins, inflammation and oxidative stress","volume":"116","author":"Tabet","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cjca.2012.03.017_bib26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","article-title":"Antiinflammatory properties of HDL","volume":"95","author":"Barter","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2012.03.017_bib27","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/hc3901.096667","article-title":"High-density lipoproteins and endothelial function","volume":"104","author":"O'Connell","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1440-1681.2010.05377.x","article-title":"High-density lipoproteins, platelets and the pathogenesis of atherosclerosis","volume":"37","author":"Nofer","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cjca.2012.03.017_bib29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.298.7.786","article-title":"High-density lipoprotein as a therapeutic target: a systematic review","volume":"298","author":"Singh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosissup.2004.08.030","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.cjca.2012.03.017_bib32","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib34","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2012.03.017_bib35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib37","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.03.017_bib38","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib39","first-page":"I-635","article-title":"Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up","volume":"98","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib40","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib41","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib42","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib44","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study","volume":"102","year":"2000","journal-title":"Circulation"},{"issue":"suppl F","key":"10.1016\/j.cjca.2012.03.017_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/eurheartj\/17.suppl_F.37","article-title":"Secondary preventive potential of lipid-lowering drugs","volume":"17","author":"de Faire","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2012.03.017_bib48","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib49","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib50","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib52","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"54","author":"Colhoun","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjca.2012.03.017_bib53","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib54","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2012.03.017_bib56","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.03.017_bib57","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1074\/jbc.273.9.5033","article-title":"Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits","volume":"273","author":"Sugano","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cjca.2012.03.017_bib58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2012.03.017_bib59","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/342448a0","article-title":"Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins","volume":"342","author":"Brown","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2012.03.017_bib60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0021-9150(85)90064-4","article-title":"Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia","volume":"58","author":"Koizumi","year":"1985","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2012.03.017_bib61","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":"Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation","volume":"323","author":"Inazu","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib62","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00041433-200012000-00004","article-title":"Pros and cons of inhibiting cholesteryl ester transfer protein","volume":"11","author":"Hirano","year":"2000","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2012.03.017_bib63","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.ATV.17.6.1053","article-title":"Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan","volume":"17","author":"Hirano","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.03.017_bib64","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","article-title":"Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels","volume":"97","author":"Zhong","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cjca.2012.03.017_bib65","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1006\/pmed.1998.0340","article-title":"A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency","volume":"27","author":"Moriyama","year":"1998","journal-title":"Prev Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib66","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCGENETICS.108.817304","article-title":"Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2012.03.017_bib68","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2012.03.017_bib69","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/CIRCULATIONAHA.109.872705","article-title":"Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community","volume":"120","author":"Vasan","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib70","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.109.875013","article-title":"Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study","volume":"121","author":"Ritsch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib71","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/eurheartj\/ehn465","article-title":"CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction","volume":"29","author":"Regieli","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2012.03.017_bib72","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib73","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.jacc.2006.06.066","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin","volume":"48","author":"McKenney","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.03.017_bib74","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib75","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib76","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib77","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/en.2008-1512","article-title":"Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition","volume":"150","author":"Hu","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.cjca.2012.03.017_bib78","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cjca.2012.03.017_bib79","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1161\/CIRCULATIONAHA.108.772665","article-title":"Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials","volume":"118","author":"Vergeer","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib80","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FJC.0b013e3181cf03cb","article-title":"Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition","volume":"55","author":"Connelly","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2012.03.017_bib81","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/HJH.0b013e32833b1f8e","article-title":"Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels","volume":"28","author":"Clerc","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2012.03.017_bib82","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib83","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2012.03.017_bib84","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjcard.2009.02.061","article-title":"Safety and tolerability of dalcetrapib","volume":"104","author":"Stein","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2012.03.017_bib86","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial","volume":"33","author":"L\u00fcscher","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2012.03.017_bib87","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11883-011-0217-9","article-title":"New horizons for cholesterol ester transfer protein inhibitors","volume":"14","author":"Schwartz","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cjca.2012.03.017_bib89","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1194\/jlr.M007468","article-title":"Biochemical characterization of cholesteryl ester transfer protein inhibitors","volume":"51","author":"Ranalletta","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cjca.2012.03.017_bib90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1185\/03007995.2010.536207","article-title":"Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation","volume":"27","author":"Kastelein","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cjca.2012.03.017_bib91","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ahj.2011.05.006","article-title":"Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"162","author":"Fayad","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2012.03.017_bib92","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ahj.2009.09.017","article-title":"Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome","volume":"158","author":"Schwartz","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2012.03.017_bib94","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib95","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies","volume":"370","author":"Krishna","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2012.03.017_bib97","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1194\/jlr.M018069","article-title":"Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure","volume":"52","author":"Cao","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cjca.2012.03.017_bib98","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.03.017_bib99","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","article-title":"Inflammatory\/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment","volume":"108","author":"Ansell","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.03.017_bib100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/pr.58.3.1","article-title":"Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis","volume":"58","author":"Kontush","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.cjca.2012.03.017_bib101","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5551\/jat.E571","article-title":"Antiatherogenic functionality of high density lipoprotein: how much versus how good","volume":"15","author":"Sviridov","year":"2008","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.cjca.2012.03.017_bib102","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1517\/17460440903008510","article-title":"Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development","volume":"4","author":"Duong","year":"2009","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.cjca.2012.03.017_bib103","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1194\/jlr.M008706","article-title":"Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport","volume":"51","author":"Niesor","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cjca.2012.03.017_bib104","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MOL.0b013e3283475e00","article-title":"Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism","volume":"22","author":"Niesor","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2012.03.017_bib105","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/ATVBAHA.110.207142","article-title":"Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2012.03.017_bib106","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib107","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","article-title":"A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome","volume":"55","author":"Waksman","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.03.017_bib108","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2012.03.017_bib109","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12001778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12001778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:38:06Z","timestamp":1760107086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X12001778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0828282X12001778"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2012.03.017","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2012.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}